X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cardiovascular (43) 43
index medicus (41) 41
humans (40) 40
cardiac & cardiovascular systems (35) 35
female (30) 30
male (30) 30
heart failure (29) 29
aged (26) 26
middle aged (23) 23
mortality (23) 23
prognosis (22) 22
cardiac patients (21) 21
abridged index medicus (18) 18
internal medicine (13) 13
prospective studies (13) 13
biomarkers (12) 12
follow-up studies (12) 12
heart attacks (12) 12
risk factors (12) 12
analysis (11) 11
heart failure - blood (11) 11
natriuretic peptides (11) 11
biomarkers - blood (10) 10
heart failure - mortality (10) 10
aged, 80 and over (9) 9
heart (9) 9
heart failure - physiopathology (9) 9
interleukin-1 receptor-like 1 protein (9) 9
cardiology (8) 8
receptors, cell surface - blood (8) 8
care and treatment (7) 7
proportional hazards models (7) 7
survival (7) 7
cardiovascular disease (6) 6
cohort studies (6) 6
diagnosis (6) 6
electrocardiography (6) 6
heart failure - diagnosis (6) 6
natriuretic peptide, brain - blood (6) 6
risk stratification (6) 6
soluble st2 (6) 6
treatment outcome (6) 6
trial (6) 6
association (5) 5
cardiology and cardiovascular medicine (5) 5
drug therapy (5) 5
electrocardiogram (5) 5
health aspects (5) 5
heart failure - complications (5) 5
heart failure - drug therapy (5) 5
medical prognosis (5) 5
multivariate analysis (5) 5
peptide fragments - blood (5) 5
research (5) 5
spain - epidemiology (5) 5
sudden cardiac death (5) 5
time factors (5) 5
acute coronary syndromes (4) 4
acute disease (4) 4
adult (4) 4
cardiac arrhythmia (4) 4
chronic heart failure (4) 4
collaboration (4) 4
confidence intervals (4) 4
disease (4) 4
epidemiology (4) 4
kaplan-meier estimate (4) 4
management (4) 4
natriuretic peptide (4) 4
outcomes (4) 4
patient outcomes (4) 4
prevalence (4) 4
public health (4) 4
quality of life (4) 4
roc curve (4) 4
stroke (4) 4
studies (4) 4
survival rate (4) 4
survival rate - trends (4) 4
therapy (4) 4
transplantation (4) 4
variables (4) 4
acute myocardial-infarction (3) 3
age (3) 3
age factors (3) 3
arrhythmia (3) 3
atrial fibrillation (3) 3
atrial fibrillation - physiopathology (3) 3
body mass index (3) 3
cardiovascular diseases (3) 3
cause of death (3) 3
chronic disease (3) 3
comorbidity (3) 3
death, sudden, cardiac - etiology (3) 3
diabetes (3) 3
disease progression (3) 3
electrocardiography, ambulatory - methods (3) 3
expression (3) 3
guidelines (3) 3
heart atria - physiopathology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 23, pp. 2174 - 2179
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2015, Volume 116, Issue 7, pp. 1071 - 1075
Journal Article
Journal Article
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2017, Volume 39, Issue 4, pp. 771 - 786.e3
Abstract Purpose Our objective was to assess the cost-effectiveness of evolocumab in patients at high risk of cardiovascular (CV) events from the Spanish... 
Internal Medicine | Medical Education | cardiovascular disease | cost-effectiveness | PCSK9 inhibitors | LDL-C | hypercholesterolemia | evolocumab | FAMILIAL HYPERCHOLESTEROLEMIA | LDL-CHOLESTEROL | 000 PARTICIPANTS | METAANALYSIS | EVENTS | EFFICACY | INDIVIDUAL DATA | STATIN THERAPY | DISEASE | PHARMACOLOGY & PHARMACY | 27 RANDOMIZED-TRIALS | Quality-Adjusted Life Years | Markov Chains | Hyperlipoproteinemia Type II - blood | Hyperlipoproteinemia Type II - economics | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Antibodies, Monoclonal - therapeutic use | Male | Spain | Cost-Benefit Analysis | Cholesterol, LDL - blood | Female | Aged | Hyperlipoproteinemia Type II - drug therapy | Antibodies, Monoclonal - economics | Cardiovascular Diseases - economics | Medicine, Experimental | Medical research | Cardiovascular diseases | Cardiac patients | Risk factors | Atherosclerosis | Hypercholesterolemia | Low density lipoproteins | Resveratrol | Markov processes | Statins | Heart | Lipoproteins (low density) | Therapy | Costs | Attitude control | Medical services | Disorders | Clinical trials | Cardiovascular disease | Risk | World Wide Web | Cost benefit analysis | Incidence | Literature reviews | Utilities | Ischemia | Mathematical models | Safety | Heart diseases | Cost engineering | Public health | Chronic illnesses | Economics | Economic models | Stroke | Receiving | Health risks | Coronary artery | Data processing | Subtilisin | Pharmacology | Patients | Coronary artery disease | Cholesterol | Quality of life | Kexin | Predictions | Death | Adults | Acute coronary syndromes | Cost analysis | Circulation
Journal Article
Journal Article